Clinical Trials Logo
  1. Home
  2. Brain Metastases, Adult
  3. NCT05480644
  4. Details
NCT05480644 Clinical Trial

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors

Brain Metastases, Adult Clinical Trial

Official title:
Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05480644
Other study ID # Pro00110602
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 1, 2022
Est. completion date December 2032

Study information
Verified date January 2024
Source Duke University
Contact Kaitlin Bailey, RN
Phone (919) 668-3726
Email Kaitlin.Bailey@duke.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this protocol is to create a repository of blood samples from patients diagnosed with primary and metastatic brain tumors who are being seen in the Department of Radiation Oncology at Duke Cancer Center.

Description:

Repository blood samples will be used to study the association of circulating biomarkers with radiation therapy outcomes.

Recruitment information / eligibility
Status Recruiting
Enrollment 300
Est. completion date December 2032
Est. primary completion date December 2032
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have a confirmed diagnosis of primary or metastatic brain tumor (histology or imaging as appropriate) Exclusion Criteria: - None

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United States Duke Cancer Center Durham North Carolina

Sponsors (1)
Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of circulating immune cells in peripheral blood reported as mean +/- standard deviation 6 weeks post radiation therapy
See also
  Status Clinical Trial Phase
Recruiting NCT05428852 - Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases N/A
Recruiting NCT05559853 - Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Recruiting NCT05689619 - SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET) N/A
Recruiting NCT04197297 - Brain Imaging Biomarkers in Patients With Brain Metastasis Phase 2
Recruiting NCT04397978 - Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
Terminated NCT04434560 - Neoadjuvant Immunotherapy in Brain Metastases Phase 2
Active, not recruiting NCT05095766 - Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
Recruiting NCT05012254 - Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases Phase 2
Recruiting NCT05789589 - Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases Phase 1/Phase 2
Recruiting NCT06280300 - Multi-disciplinary Care for Brain Metastases N/A
Recruiting NCT06047379 - Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Phase 1/Phase 2
Completed NCT03896555 - Intrafractional Head Movement During Radiosurgery
Terminated NCT03789149 - Focal Intraoperative Radiotherapy of Brain Metastases Phase 2
Recruiting NCT04343157 - UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases Phase 2
Recruiting NCT04711824 - Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases Phase 1/Phase 2
Recruiting NCT05793489 - Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin N/A
Recruiting NCT04461418 - Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases Phase 2
Active, not recruiting NCT03818386 - Radiotherapy of Multiple Brain Metastases Using AGuIX® Phase 2
Active, not recruiting NCT05087095 - Managing Distress in Malignant Brain Cancer N/A
Recruiting NCT04396717 - Safety Study of Pritumumab in Brain Cancer Phase 1